PriceTargets.com logo

INVO Bioscience - INVO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.80 As of 12/17/2024 01:00 AM ET
▼ -0.02 (-2.44%)

This chart shows the closing price for INVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New INVO Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INVO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for INVO Bioscience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.80.

This chart shows the closing price for INVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in INVO Bioscience. This rating has held steady since March 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/26/2022Maxim GroupLower Target$60.00
4/13/2022Roth CapitalDowngradeBuy ➝ Neutral$80.00 ➝ $40.00
3/22/2022Colliers SecuritiesReiterated RatingBuy
1/19/2022Maxim GroupInitiated CoverageBuy$140.00
8/18/2021Roth CapitalLower TargetBuy$115.00 ➝ $105.00
12/29/2020Roth CapitalReiterated RatingBuy
12/29/2020Roth CapitalInitiated CoverageBuy
12/15/2020Colliers SecuritiesReiterated RatingBuy
12/15/2020Colliers SecuritiesInitiated CoverageBuy
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
INVO Bioscience logo
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
Read More

Today's Range

Now: $0.80
Low: $0.80
High: $0.80

50 Day Range

MA: $0.87
Low: $0.66
High: $1.24

52 Week Range

Now: $0.80
Low: $0.63
High: $3.50

Volume

112,657 shs

Average Volume

1,587,563 shs

Market Capitalization

$3.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of INVO Bioscience?

The following sell-side analysts have issued research reports on INVO Bioscience in the last twelve months:
View the latest analyst ratings for INVO.

What is the current price target for INVO Bioscience?

0 Wall Street analysts have set twelve-month price targets for INVO Bioscience in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for INVO Bioscience in the next year.
View the latest price targets for INVO.

What is the current consensus analyst rating for INVO Bioscience?

INVO Bioscience currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INVO.

What other companies compete with INVO Bioscience?

Other companies that are similar to INVO Bioscience include STRATA Skin Sciences, Lyra Therapeutics, PolyPid, PetVivo and SeaStar Medical. Learn More about companies similar to INVO Bioscience.

How do I contact INVO Bioscience's investor relations team?

INVO Bioscience's physical mailing address is 5582 BROADCAST COURT, SARASOTA FL, 34240. The company's listed phone number is (978) 878-9505 and its investor relations email address is [email protected]. The official website for INVO Bioscience is www.invobioscience.com. Learn More about contacing INVO Bioscience investor relations.